Pharmaceutical Product Guide » ASP8825 http://www.pharmaceuticalproductguide.com/blog A comprehensive guide to pharmaceutical products for medical professionals Fri, 11 Jun 2010 09:15:33 +0000 http://wordpress.org/?v=2.8.2 en hourly 1 Astellas and XenoPort Announce Submission of a New Drug Application in Japan http://www.pharmaceuticalproductguide.com/blog/2009/12/16/astellas-and-xenoport-announce-submission-of-a-new-drug-application-in-japan/ http://www.pharmaceuticalproductguide.com/blog/2009/12/16/astellas-and-xenoport-announce-submission-of-a-new-drug-application-in-japan/#comments Thu, 17 Dec 2009 04:50:21 +0000 Kimberly O'Brien http://www.pharmaceuticalproductguide.com/blog/?p=175 Astellas Pharma IncAstellas Pharma Inc. and XenoPort, Inc. have announced that a new drug application (NDA) has been filed with the Pharmaceuticals and Medical Device Agency (PMDA) in Japan for ASP8825 (gabapentin enacarbil), also known as XP13512, as a potential treatment for restless legs syndrome (RLS). The acceptance of filing of the NDA triggers a $5 million milestone payment from Astellas to XenoPort.

For the full story, Click Here

]]> http://www.pharmaceuticalproductguide.com/blog/2009/12/16/astellas-and-xenoport-announce-submission-of-a-new-drug-application-in-japan/feed/ 0